Bayer HealthCare’s regorafenib receives orphan medication status for GIST treatment Bayer Health care Pharmaceuticals Inc. Announced today that its investigational substance regorafenib provides been granted orphan medication status for the treating individuals with gastrointestinal stromal tumors by the U facts about drugs .S. Food and Medication Administration . Regorafenib can be an investigational agent and isn’t accepted by the FDA, the European Medicines Company or other Wellness Authorities.
Bayer HealthCare’s goal is to find and manufacture items that may improve human and pet health world-wide. Find more info at Bayer Schering Pharma is normally an internationally leading specialty pharmaceutical organization. Its study and business actions are focused on the next areas: Diagnostic Imaging, General Medicine, Specialty Medication and Women’s Health care. With innovative items, Bayer Schering Pharma aims for leading positions in specific markets worldwide. Using brand-new ideas, Bayer Schering Pharma aims to produce a contribution to medical strives and get to improve the standard of life. Find more info at.. Bayer starts pivotal Stage III trial with Florbetaben Bayer Schering Pharma AG, Germany, is progressing with the advancement of florbetaben to aid Alzheimer analysis.